Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Data from two Phase III clinical trials have supported the use of Perforomist inhalation solution as a safe and effective maintenance treatment for chronic obstructive pulmonary disease.
Subscribe to our email newsletter
Twice-daily delivery of nebulized formoterol fumarate was well tolerated over a 12-month treatment period in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Perforomist inhalation solution is the first and only FDA-approved nebulized form of Formoterol fumarate, a rapid and long-acting beta(2)-agonist.
James Donohue, chief of pulmonary medicine at the University of North Carolina at Chapel Hill, said: “The study’s findings indicate that nebulized delivery of formoterol fumarate is a safe long-term treatment option for patients with moderate-to- severe COPD who may prefer or require nebulization. Physicians should feel confident offering Perforomist inhalation solution as an additional therapeutic choice for COPD patients with moderate-to-severe disease.”
The results were included as part of the new drug application filing to the FDA for Perforomist inhalation solution.